Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
Eton Pharmaceuticals (Nasdaq: ETON) announced it will report its second quarter 2026 financial results on Thursday, August 13, 2026.
Rhea-AI Summary
Eton Pharmaceuticals (Nasdaq: ETON) announced it will report its second quarter 2026 financial results on Thursday, August 13, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET (3:30 p.m. CT) to discuss the results and take investor questions.
Investors may submit questions by email to investorrelations@etonpharma.com. The live webcast and a 30-day archive will be available in the Investors section of Eton’s website at https://ir.etonpharma.com/.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ETON
In the Aug 3 session, ETON declined 2.76%, reflecting a moderate negative market reaction. Argus tracked a trough of -2.3% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Reporting period
- Q2 2026
- Financial results scheduled for release
- Results date
- August 13, 2026
- Thursday reporting date
- Conference call time
- 4:30 p.m. ET / 3:30 p.m. CT
- Management discussion of results
- Webcast archive timing
- 2 hours
- Approximate delay after event completion
- Archive availability
- 30 days
- Archived webcast availability on company website
Previous Earnings date Reports
-
Announced first-quarter 2026 results date and conference call schedule
-
Announced fourth-quarter and full-year 2025 results date and webcast schedule
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DEER PARK, Ill., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2026 financial results on Thursday, August 13, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
| Participant Call Link: | Click Here | |
| Webcast: | Click Here | |
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can also be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eleven commercial rare disease products: KHINDIVI®, INCRELEX®, ALKINDI SPRINKLE®, DESMODA™, GALZIN®, HEMANGEOL®, PKU GOLIKE®, IMPAVIDO®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Investor Relations:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.